About MD NAD: an independent digest of the clinical NAD+ research record

MD NAD is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ — nicotinamide adenine dinucleotide — including its precursors NMN and NR, its intravenous and injectable administration literature, and the mechanistic science underlying its role in aging, DNA repair, and cellular metabolism.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — primary literature in peer-reviewed journals, clinical trial publications, and regulatory documents.

The 'MD' in our name is editorial framing — it signals that this digest is aimed at a clinician-facing register, covering the clinical trial evidence, infusion protocols, and pharmacokinetic data that practitioners and researchers consult. It is not a claim about the site's services. We have no clinical staff, no physicians on staff, and we provide no medical services of any kind.

Every quantitative claim on this site is cited to a specific peer-reviewed publication, with PubMed link or DOI. The citation list is on the references page. The FAQ page covers the most frequently asked clinical questions. Research is on the /research page. IV protocol evidence is at NAD+ IV therapy. Injectable route information is at NAD+ injection protocols.

NAD+ is the compound with the largest active clinical trial footprint of any non-approved longevity compound as of 2026: more than 18 completed human RCTs for oral NMN and NR alone, plus IV infusion pilot studies, case series in addiction medicine, and emerging SC/IM injection trials. The evidence base is unusually detailed, the mechanism is unusually well-characterized, and the clinical translation questions are unusually specific — which tissues benefit, which routes are superior, which precursor is more bioavailable in which population.

That specificity makes the editorial challenge interesting. The NAD+ internet is crowded with marketing — from supplement vendors who overstate the mouse-to-human translation, and from wellness practices that have gotten ahead of the controlled trial record. MD NAD reads the primary literature and reports what the studies actually measured: effect sizes, doses, populations, and open questions. The chrome and iridescence of this site's visual language is the opposite of its editorial posture: the site looks like a longevity console and reads like a research digest.

We cover NMN, NR, nicotinamide riboside, nicotinamide mononucleotide, and intravenous and injectable NAD+ protocols as documented in the peer-reviewed literature. We do not cover GLP-1 compounds, peptides, or other unrelated research categories — NAD+ is a coenzyme, structurally and pharmacologically distinct from the peptide and incretin drug categories.

MD NAD is not a medical practice. We do not diagnose, treat, prevent, or cure any condition. We do not recommend dosing, routes of administration, or treatment protocols to any individual. The research framing on this site — doses administered in which trials to which populations — describes what was studied, not what you should take.

We are not a vendor. We do not sell NAD+, NMN, NR, or any related product. We have no affiliate relationships with supplement companies. No link on this site earns a commission.

We are not a compounding pharmacy. We do not formulate, compound, or distribute any injectable or IV preparation.

If you are a patient or individual seeking guidance on NAD+ supplementation or IV therapy, you should consult a licensed healthcare provider. The published literature is the basis for this site's content; a clinician with knowledge of your individual health situation is the appropriate guide for any personal health decision.